Drug Trial Radar · NCT06897358
Leniolisib for Immune Dysregulation in CVID
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Feb 12, 2025
Primary completion
Aug 12, 2026
Study completion Aug 12, 2026
Sponsor
- Lead sponsor
- Pharming Technologies B.V.Industry
- Sponsor type
- Industry
- Collaborators
- Lahey Hospital & Medical Center
- First posted
- Mar 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, common variable immunodeficiency (CVID) patients will all receive the study drug, leniolisib, for a treatment period of 6 months. Participants will start on a lower dose of leniolisib, followed by a mid and then a higher dose level. The primary goal is to assess the safety and tolerability of leniolisib, and secondary goal is to assess the potential for leniolisib to provide benefits for patients.
Conditions
- Common Variable Immunodeficiency (CVID)
Interventions
LeniolisibDrug
Planned dose will range from 10 mg twice daily to 70 mg twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety & TolerabilityTime frame: From baseline to the end of 24 weeks of treatment
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado
National Institute of Health
Bethesda, Maryland
Lahey Hospital & Medical Center
Burlington, Massachusetts
Mount Sinai Hospital
New York, New York
Texas Children's Hospital
Houston, Texas
IIS La Fe
Valencia, Spain
Leeds Teaching Hospital NHS Trust
Leeds, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.